Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01691807 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
A Phase 1 study of Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT01691807 is a Phase 1 study of Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 30 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT01691807, a Phase 1 study of Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the potential drug-drug interactions between ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell non-Hodgkin's lymphoma (NHL).
Conditions Studied
Interventions
- DRUG bendamustine
- DRUG ofatumumab
Study Locations (5)
Texas
- Novartis Investigative Site - Houston
- Novartis Investigative Site - San Antonio
Alabama
- Novartis Investigative Site - Birmingham
Mississippi
- Novartis Investigative Site - Southaven
West Virginia
- Novartis Investigative Site - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01691807
The ClinicalTrials.gov registry entry for NCT01691807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which bendamustine is the first listed.
NCT01691807 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Alabama, Mississippi.
Frequently Asked Questions
What is clinical trial NCT01691807 about?
NCT01691807 is a clinical study titled "Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma". The purpose of this study is to evaluate the potential drug-drug interactions between ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell non-Hodgkin's lymphoma (NHL).
What is the current status of trial NCT01691807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2013-01. Estimated completion is 2015-12.
What conditions does trial NCT01691807 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01691807?
The interventions under investigation include: bendamustine (DRUG), ofatumumab (DRUG).
Who is sponsoring clinical trial NCT01691807?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01691807 being conducted?
This trial has 5 study locations across Alabama, Mississippi, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.